0001193125-16-807397.txt : 20161229 0001193125-16-807397.hdr.sgml : 20161229 20161229165157 ACCESSION NUMBER: 0001193125-16-807397 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20161130 FILED AS OF DATE: 20161229 DATE AS OF CHANGE: 20161229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGEN CORP CENTRAL INDEX KEY: 0000711377 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 382367843 STATE OF INCORPORATION: MI FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-17988 FILM NUMBER: 162075631 BUSINESS ADDRESS: STREET 1: 620 LESHER PLACE CITY: LANSING STATE: MI ZIP: 48912 BUSINESS PHONE: 5173729200 MAIL ADDRESS: STREET 1: 620 LESHER PLACE CITY: LANSING STATE: MI ZIP: 48912 10-Q 1 d298040d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended November 30, 2016.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-17988

Neogen Corporation

(Exact name of registrant as specified in its charter)

Michigan

38-2367843

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification Number)

620 Lesher Place

Lansing, Michigan 48912

(Address of principal executive offices, including zip code)

(517) 372-9200

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (see definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): YES ☐ NO ☒

As of November 30, 2016, there were 37,970,778 shares of Common Stock outstanding.

NEOGEN CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS


		Page No.
PART I. FINANCIAL INFORMATION

Item 1.	Interim Consolidated Financial Statements (unaudited)		2

	Consolidated Balance Sheets – November 30, 2016 and May 31, 2016		2

	Consolidated Statements of Income – Three and six months ended November 30, 2016 and 2015		3

	Consolidated Statements of Comprehensive Income – Three and six months ended November 30, 2016 and 2015		4

	Consolidated Statement of Equity – Six months ended November 30, 2016		5

	Consolidated Statements of Cash Flows – Six months ended November 30, 2016 and 2015		6

	Notes to Interim Consolidated Financial Statements – November 30, 2016		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		19

Item 4.	Controls and Procedures		19

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings		20

Item 6.	Exhibits		20

SIGNATURES			21

	CEO Certification

	CFO Certification

	Section 906 Certification

PART I – FINANCIAL INFORMATION

Item 1. Interim Consolidated Financial Statements

Neogen Corporation and Subsidiaries

Consolidated Balance Sheet

(in thousands, except share and

per share amounts)


	November 30, 2016			May 31, 2016
	(Unaudited)			(Audited)
Assets
Current Assets
Cash and cash equivalents	$	86,297		$	55,257
Marketable securities (at fair value, which approximates cost)		55,809			52,539
Accounts receivable, less allowance of $1,650 and $1,500		64,902			67,652
Inventories		71,683			64,371
Deferred income taxes		1,748			1,775
Prepaid expenses and other current assets		7,962			8,407

Total Current Assets		288,401			250,001
Net Property and Equipment		55,533			54,683
Other Assets
Goodwill		87,581			88,506
Other non-amortizable intangible assets		9,370			9,170
Amortizable customer-based intangibles, net of accumulated amortization of $18,186 and $17,277 at November 30, 2016 and May 31, 2016		27,271			30,909
Other non-current assets, net of accumulated amortization of $9,768 and $7,530 at November 30, 2016 and May 31, 2016		19,155			18,446

Total Assets	$	487,311		$	451,715

Liabilities and Equity
Current Liabilities
Accounts payable		17,287			15,800
Accrued compensation		4,442			4,986
Income taxes		1,383			—
Other accruals		10,757			7,812

Total Current Liabilities		33,869			28,598
Deferred Income Taxes		16,418			16,533
Other Long-Term Liabilities		2,251			2,423

Total Liabilities		52,538			47,554
Commitments and Contingencies (note 7)		—			—
Equity
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding		—			—
Common stock, $0.16 par value, 60,000,000 shares authorized, 37,970,778 and 37,567,689 shares issued and outstanding at November 30, 2016 and May 31, 2016, respectively		6,076			6,011
Additional paid-in capital		163,626			150,000
Accumulated other comprehensive loss		(8,130	)		(3,946	)
Retained earnings		273,165			252,133

Total Neogen Corporation Stockholders’ Equity		434,737			404,198
Non-controlling interest		36			(37	)

Total Equity		434,773			404,161

Total Liabilities and Equity	$	487,311		$	451,715

See notes to interim consolidated financial statements.

Neogen Corporation and Subsidiaries

Consolidated Statements of Income (unaudited)

(in thousands, except per share amounts)


	Three Months Ended						Six Months Ended
	November 30,						November 30,
	2016			2015			2016			2015
Revenues
Product revenues	$	76,961		$	68,717		$	149,206		$	133,754
Service revenues		13,756			10,893			25,156			20,717

Total Revenues		90,717			79,610			174,362			154,471
Cost of Revenues
Cost of product revenues		38,890			34,006			74,425			64,637
Cost of service revenues		8,236			7,380			15,867			13,818

Total Cost of Revenues		47,126			41,386			90,292			78,455

Gross Margin		43,591			38,224			84,070			76,016
Operating Expenses
Sales and marketing		15,687			14,203			30,484			27,774
General and administrative		8,284			6,791			16,546			13,543
Research and development		2,768			2,618			5,446			5,192

Total Operating Expenses		26,739			23,612			52,476			46,509

Operating Income		16,852			14,612			31,594			29,507
Other Income (Expense)
Interest income		296			51			419			119
Other income (expense)		(377	)		(471	)		(8	)		(995	)

Total Other Income (Expense)		(81	)		(420	)		411			(876	)
Income Before Taxes		16,771			14,192			32,005			28,631
Provision for Income Taxes		5,600			5,050			10,900			10,200

Net Income		11,171			9,142			21,105			18,431
Net (Income) Loss Attributable to Non-Controlling Interest		(20	)		(69	)		(73	)		(35	)

Net Income Attributable to Neogen	$	11,151		$	9,073		$	21,032		$	18,396

Net Income Attributable to Neogen Per Share
Basic	$	0.29		$	0.24		$	0.56		$	0.49

Dilluted	$	0.29		$	0.24		$	0.55		$	0.49

See notes to interim consolidated financial statements.

Neogen Corporation and Subsidiaries

Consolidated Statements of Comprehensive Income (unaudited)

(in thousands)


	Three Months Ended						Six Months Ended
	November 30,						November 30,
	2016			2015			2016			2015
Net income	$	11,171		$	9,142		$	21,105		$	18,431
Other comprehensive income (loss), net of tax: currency translation adjustments		(1,606	)		(294	)		(4,184	)		(1,007	)

Comprehensive income		9,565			8,848			16,921			17,424
Comprehensive (income) loss attributable to non-controlling interest		(20	)		(69	)		(73	)		(35	)

Comprehensive income attributable to Neogen Corporation	$	9,545		$	8,779		$	16,848		$	17,389

See notes to interim consolidated financial statements.

Neogen Corporation and Subsidiaries

Consolidated Statement of Equity (unaudited)

(in thousands)


							Accumulated
					Additional		Other					Non-
	Common Stock				Paid-in		Comprehensive			Retained		controlling
	Shares		Amount		Capital		Income (Loss)			Earnings		Interest			Total
Balance, May 31, 2016		37,568	$	6,011	$	150,000	$	(3,946	)	$	252,133	$	(37	)	$	404,161
Exercise of options, share based compensation and $2,476 income tax benefit		394		64		13,199										13,263
Issuance of shares under employee stock purchase plan		9		1		427										428
Net income for the six months ended November 30, 2016											21,032		73			21,105
Other comprehensive loss								(4,184	)							(4,184	)

Balance November 30, 2016		37,971	$	6,076	$	163,626	$	(8,130	)	$	273,165	$	36		$	434,773

See notes to interim consolidated financial statements.

Neogen Corporation and Subsidiaries

Consolidated Statements of Cash Flows (unaudited)

(in thousands)


	Six Months Ended
	November 30,
	2016			2015
Cash Flows From Operating Activities
Net Income	$	21,105		$	18,431
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization		7,038			5,680
Share based compensation		2,734			2,545
Excess income tax benefit from the exercise of stock options		(2,476	)		(2,443	)
Change in operating assets and liabilities, net of business acquisitions:
Accounts receivable		1,847			2,514
Inventories		(7,963	)		(8,784	)
Prepaid expenses and other current assets		428			(1,858	)
Accounts payable, accruals and other changes		6,836			4,776

Net Cash From Operating Activities		29,549			20,861
Cash Flows Used In Investing Activities
Purchases of property, equipment and other non-current intangible assets		(6,238	)		(7,815	)
Proceeds from the sale of marketable securities		64,522			80,379
Purchases of marketable securities		(67,792	)		(83,916	)
Business acquisitions, net of cash acquired		(437	)		(13,554	)

Net Cash Used In Investing Activities		(9,945	)		(24,906	)
Cash Flows From Financing Activities
Exercise of stock options		10,345			6,611
Excess income tax benefit from the exercise of stock options		2,476			2,443

Net Cash From Financing Activities		12,821			9,054
Effect of Exchange Rate on Cash		(1,385	)		308
Net Increase In Cash and Cash Equivalents		31,040			5,317
Cash And Cash Equivalents At Beginning Of Period		55,257			66,061

Cash And Cash Equivalents At End Of Period	$	86,297		$	71,378

See notes to interim consolidated financial statements.

NEOGEN CORPORATION AND SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the six month period ended November 30, 2016 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2017. For more complete financial information, these consolidated financial statements should be read in conjunction with the May 31, 2016 audited consolidated financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended May 31, 2016.

2. INVENTORIES

Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories follow:


	November 30,		May 31,
	2016		2016
	(in thousands)
Raw Materials	$	31,881	$	29,501
Work-in-process		5,588		4,498
Finished and purchased goods		34,214		30,372

	$	71,683	$	64,371

3. NET INCOME PER SHARE

The calculation of net income per share attributable to Neogen Corporation follows:


	Three Months Ended				Six Months Ended
	November 30,				November 30,
	2016		2015		2016		2015
	(in thousands, except per share amounts)
Numerator for basic and diluted net income per share-
Net income attributable to Neogen	$	11,151	$	9,073	$	21,032	$	18,396
Denominator for basic net income per share-
Weighted average shares		37,816		37,390		37,715		37,301
Effect of dilutive stock options		446		478		468		509

Denominator for diluted net income per share		38,262		37,868		38,183		37,810
Net income attributable to Neogen per share:
Basic	$	0.29	$	0.24	$	0.56	$	0.49

Diluted	$	0.29	$	0.24	$	0.55	$	0.49

4. SEGMENT INFORMATION

The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors; this segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

These segments are managed separately because they represent strategic business units that offer different products and require different marketing strategies. The Company evaluates performance based on total sales and operating income of the respective segments. The accounting policies of each of the segments are the same as those described in Note 1.

Segment information follows:


					Corporate and
	Food		Animal		Eliminations
	Safety		Safety		(1)			Total
	(in thousands)
As of and for the three months ended November 30, 2016
Product revenues to external customers	$	37,279	$	39,682	$	—		$	76,961
Service revenues to external customers		3,482		10,274		—			13,756

Total revenues to external customers		40,761		49,956		—			90,717
Operating income (loss)		8,979		8,998		(1,125	)		16,852
Total assets		142,303		217,572		127,436			487,311
As of and for the three months ended November 30, 2015
Product revenues to external customers	$	34,682	$	34,035	$	—		$	68,717
Service revenues to external customers		2,572		8,321		—			10,893

Total revenues to external customers		37,254		42,356		—			79,610
Operating income (loss)		7,687		7,833		(908	)		14,612
Total assets		132,472		182,478		110,833			425,783


					Corporate and
	Food		Animal		Eliminations
	Safety		Safety		(1)			Total
	(in thousands)
For the six months ended November 30, 2016
Product revenues to external customers	$	72,921	$	76,285	$	—		$	149,206
Service revenues to external customers		6,843		18,313		—			25,156

Total revenues to external customers		79,764		94,598		—			174,362
Operating income (loss)		17,062		16,694		(2,162	)		31,594
For the six months ended November 30, 2015
Product revenues to external customers	$	66,733	$	67,021	$	—		$	133,754
Service revenues to external customers		4,981		15,736		—			20,717

Total revenues to external customers		71,714		82,757		—			154,471
Operating income (loss)		16,108		15,173		(1,774	)		29,507

(1)	Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

5. EQUITY COMPENSATION PLANS

Qualified and non-qualified options to purchase shares of common stock may be granted to directors, officers and employees of the Company under the terms of the Company’s stock option plans. These options are granted at an exercise price of not less than the fair market value of the stock on the date of grant. Options vest ratably over three and five year periods and the contractual terms are generally five or ten years. A summary of stock option activity during the six months ended November 30, 2016 follows:


				Weighted-
				Average
	Shares			Exercise Price
Options outstanding June 1, 2016		2,081,000		$	36.71
Granted		607,000			53.99
Exercised		(403,000	)		28.21
Forfeited		(33,000	)		40.84

Options outstanding November 30, 2016		2,252,000			42.83

During the three and six month periods ended November 30, 2016 and 2015 the Company recorded $1,218,000 and $1,248,000 and $2,734,000 and $2,545,000, respectively, of compensation expense related to its share based awards.

The weighted-average fair value per share of stock options granted during fiscal 2017 and fiscal 2016, estimated on the date of grant using the Black-Scholes option pricing model was $15.79 and $13.11, respectively. The fair value of stock options granted was estimated using the following weighted-average assumptions.


	FY2017			FY2016
Risk-free interest rate		1.2	%		1.2	%
Expected dividend yield		0.0	%		0.0	%
Expected stock price volatility		35.2	%		33.3	%
Expected option life		4.0 years			4.0 years

The Company has an employee stock purchase plan that provides for employee stock purchases at a 5% discount to market price. The discount is recorded in administrative expense as of the date of purchase.

6. NEW ACCOUNTING PRONOUNCEMENTS

In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers. The new standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. In April 2016, the FASB issued Accounting Standards Update No. 2016-10— Revenue from Contracts with Customers (Topic 606), which amends and adds clarity to certain aspects of the guidance set forth in ASU 2014-09 related to identifying performance obligations and licensing. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is not permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11—Inventory: Simplifying the Measurement of Inventory. The update requires inventory not measured using either the last in, first out (LIFO) or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal and transportation. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company is currently evaluating the impact of ASU 2015-11 on its consolidated financial condition and results of operations.

In September 2015, the FASB issued ASU 2015-16—Simplifying the Accounting for Measurement - Period Adjustments. Changes to the accounting for measurement-period adjustments relate to business combinations. Currently, an acquiring entity is required to retrospectively adjust the balance sheet amounts of the acquiree recognized at the acquisition date with a corresponding adjustment to goodwill as a result of changes made to the balance sheet amounts of the acquiree. The measurement period is the period after the acquisition date during which the acquirer may adjust the balance sheet amounts recognized for a business combination (generally up to one year from the date of acquisition). The changes eliminate the requirement to make such retrospective adjustments, and instead require the acquiring entity to record these adjustments in the reporting period they are determined. The new standard is effective for public companies for fiscal years beginning after December 15, 2015. The Company has adopted this standard, which does not have a material impact on its consolidated financial condition and results of operations.

The FASB recently issued ASU No. 2015-17—Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes as part of its Simplification Initiative. The amendments eliminate the guidance in Topic 740, Income Taxes, that required an entity to separate deferred tax liabilities and assets between current and noncurrent amounts in a classified balance sheet. Rather, deferred taxes will be presented as noncurrent under the new standard. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017 for public companies. Early adoption is permitted. The Company does not believe that adoption of this standard will have a material impact on its consolidated financial condition.

In February 2016, the FASB issued ASU No. 2016-02—Leases to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous U.S. GAAP. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018. Modified retrospective application is permitted with certain practical expedients. Early adoption is permitted. The Company is currently evaluating the impact of ASU No. 2016-02 on its consolidated financial condition and results of operations.

In March 2016, the FASB issued ASU No. 2016-09 — Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting to provide guidance that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid-in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 with early adoption permitted. The Company is currently evaluating the impact of ASU No. 2016-09 on its consolidated financial condition and results of operations.

In August 2016, the FASB issued ASU No. 2016-15— Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force). The amendments in ASU 2016-15 address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows under FASB Accounting Standards Codification (FASB ASC) 230, Statement of Cash Flows. The amendments in ASU 2016-15 are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption during an interim period. The Company has not yet adopted this update and is currently evaluating the impact of ASU No. 2016-15 on its consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16 — Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory which requires companies to account for income tax effects of intercompany transactions other than inventory in the period in which the transfer occurs. This is a change from current GAAP, which requires companies to defer the income tax effects of intercompany transfers of assets until the asset has been sold to an outside party or otherwise recognized (i.e. depreciation, amortization, impaired). ASU 2016-16 will still require companies to defer the income tax effects of intercompany inventory transactions. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company has not yet adopted this update and is currently evaluating the impact of ASU No. 2016-16 on its consolidated financial statements.

7. BUSINESS AND PRODUCT LINE ACQUISITIONS

The Consolidated Statements of Income reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method. Goodwill recognized in the acquisitions discussed below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings.

On October 1, 2014, the Company acquired all of the stock of BioLumix, Inc., a manufacturer and marketer of automated systems for the detection of microbial contaminants located in Ann Arbor, Michigan. Consideration for the purchase was $4,514,000 in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $499,000, other receivable of $178,000, net inventory of $421,000, prepaid assets of $48,000, property and equipment of $159,000, current liabilities of $155,000, long-term liabilities of $780,000, intangible assets of $2,090,000 (with an estimated life of 5-15 years) and the remainder to goodwill (non-deductible for tax purposes). These values are Level 3 fair value measurements. This business was relocated to Lansing, Michigan and integrated with the Company’s operations there, reporting within the Food Safety segment.

On December 8, 2014, the Company acquired the food safety and veterinary genomic assets of its Chinese distributor Beijing Anapure BioScientific Co., Ltd. Consideration for the purchase was $2,040,000 in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $525,000, property and equipment of $64,000, intangible assets of $422,000 (with an estimated life of 5-15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business was integrated into the Company’s subsidiary in China and reports within the Food Safety segment.

On June 1, 2015, the Company acquired the assets of Sterling Test House, a commercial food testing laboratory based in India. Consideration for the purchase was $1,118,000 in cash and approximately $102,000 of a contingent consideration liability, due in installments on the first two anniversary dates, based on an excess sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $43,000, inventory of

$14,000, property and equipment of $141,000, contingent consideration accrual of $102,000, intangible assets of $345,000 (with an estimated life of 5-15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and reports within the Animal Safety segment. In July 2016, the Company paid the former owner $70,000 for contingent consideration based on the achievement of sales targets, and reduced the recorded liability by a corresponding amount.

On August 26, 2015, the Company acquired all of the stock of Lab M Holdings, a developer, manufacturer and supplier of microbiological culture media and diagnostic systems located in the United Kingdom. Consideration for the purchase was $12,436,000 in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included cash of $285,000, accounts receivable of $975,000, inventory of $1,169,000, property and equipment of $3,337,000, other current assets of $309,000, current liabilities of $948,000, long-term deferred tax liability of $784,000, intangible assets of $3,611,000 (with an estimated life of 5-15 years) and the remainder to goodwill (non-deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and reports within the Food Safety segment.

On December 22, 2015, the Company acquired the rodenticide assets of Virbac Corporation, the North American affiliate of the France-based Virbac group, a global animal health company. The acquired assets include a rodenticide active ingredient that complements Neogen’s existing active ingredients, and more than 40 regulatory approvals for a variety of formulations in the United States, Canada and Mexico. The acquired assets also include a large retail and OEM customer base. Consideration for the purchase was $3,525,000 in cash and up to $300,000 of contingent consideration. The preliminary purchase price allocation included inventory of $317,000, property and equipment of $60,000, intangible assets of $2,545,000 (with an estimated life of 5-15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. The products are manufactured at the Company’s production facility in Randolph, Wisconsin and reports within the Animal Safety segment.

On April 26, 2016, the Company acquired the stock of Deoxi Biotecnologia Ltda., an animal genomics laboratory located in Aracatuba, Brazil. Deoxi was a competitor of Neogen’s in the livestock genomics market and this acquisition is intended to help accelerate the growth of Neogen’s animal genomics services in Brazil. Consideration for the purchase was $1,549,000 in cash and up to $2,552,000 of contingent consideration, due at the end of each of the first two years, based on an excess net sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $132,000, inventory of $89,000, other current assets of $9,000, property and equipment of $232,000, current liabilities of $266,000, contingent consideration liabilities of $453,000, non-amortizable trademarks of $193,000,

intangible assets of $350,000 (with an estimated life of 5-10 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and reports within the Food Safety segment.

On May 1, 2016, the Company acquired the stock of Preserve International and its sister company, Tetradyne LLC, manufacturers and marketers of cleaners, disinfectants and associated products to the swine, poultry, food processing and dairy markets. Preserve and Tetradyne have manufacturing locations in Memphis, Tennessee and Turlock, California. Consideration for the purchase was

$24,086,000 in cash. The preliminary purchase price allocation included accounts receivable of $1,629,000, inventory of $1,964,000, other current assets of $269,000, land, property and equipment of $1,625,000, current liabilities of $868,000, long-term liabilities of

$660,000, intangible assets of $10,590,000 (with an estimated life of 5-15 years) and the remainder to goodwill (partially deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current locations and reports within the Animal Safety segment.

On December 1, 2016 subsequent to the end of the second quarter, Neogen acquired the stock of Quat-Chem Ltd., a chemical company that manufactures biosecurity products, based in Rochdale, England. Consideration for the purchase was $20,500,000 in cash. Due to the timing of the transaction, the preliminary purchase price allocation was not complete at the time of filing.

On December 27, 2016 subsequent to the end of the second quarter, Neogen completed the acquisition of the stock of Rogama Industria e Comercio, Ltda., a company that develops and manufactures rodenticides and insecticides, based near Sao Paulo, Brazil. Consideration for the purchase was $13 million in cash. Due to the timing of the transaction, the preliminary purchase price allocation was not complete at the time of filing.

8. LONG TERM DEBT

The Company has a financing agreement with a bank providing for an unsecured revolving line of credit, which was amended on November 30, 2016 to increase the line from $12,000,000 to $15,000,000, and extend the maturity from September 1, 2017 to September 30, 2019. There were no advances against the line of credit during fiscal 2016 and there have been none thus far in fiscal 2017; there is no balance outstanding at November 30, 2016. Interest on any borrowings remained at LIBOR plus 100 basis points (rate under the terms of the agreement was 1.77% at November 30, 2016). Financial covenants include maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the Company was in compliance with at November 30, 2016.

9. COMMITMENTS AND CONTINGENCIES

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company expenses annual costs of remediation, which have ranged from $47,000 to $57,000 per year over the past five years. The Company’s estimated liability for these costs is $916,000 at November 30, 2016 and May 31, 2016, measured on an undiscounted basis over an estimated period of 15 years; $60,000 of the liability is recorded within current liabilities and the remainder is recorded within other long-term liabilities in the consolidated balance sheet.

The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position.

10. STOCK PURCHASE

The Company has a stock repurchase program, authorized by the Board of Directors in calendar year 2008, to purchase, subject to market conditions, up to 1,125,000 shares of the Company’s common stock. As of November 30, 2016, 1,012,974 shares are available to be repurchased under the program. There were no purchases in fiscal year 2016 and there have been none thus far in fiscal 2017.

PART I – FINANCIAL INFORMATION

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

Safe Harbor and Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

In addition, any forward-looking statements represent management’s views only as of the day this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

Critical Accounting Policies and Estimates

The discussion and analysis of the Company’s financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, those related to receivable allowances, inventories, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There were no significant changes to our contractual obligations or contingent liabilities and commitments disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2016.

There have been no material changes to the critical accounting policies and estimates disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2016.

Executive Overview

Revenues for the Company for the second quarter ended November 30, 2016 were $90.7 million, an increase of 14%, or $11.1 million, compared to revenues of $79.6 million for the same period in the prior year. For the year to date period, revenues were $174.4 million, an increase of 13%, or $19.9 million, compared to revenues of $154.5 million in the first six months of fiscal 2016. Net income attributable to Neogen for the second quarter of fiscal 2017 increased 23% to $11.2 million, or $0.29 per fully diluted share, compared to $9.1 million, or $0.24, in the second quarter of the prior fiscal year. For the first six months of the current fiscal year, net income attributable to Neogen increased 14% to $21.0 million, or $0.55 per fully diluted share, compared to $18.4 million, or $0.49, in the same period in fiscal 2016.

For the three month period ended November 30, 2016, Food Safety revenues increased 9% and Animal Safety revenues increased 18%, each compared to the same period in the prior year. For the quarter, the overall organic sales increase was 7%; organic growth in the Food Safety segment was 8% while the Animal Safety segment had organic growth of 5%. The acquisitions of Virbac (December 2015), Deoxi (April 2016) and Preserve/Tetradyne (May 2016) contributed $5.9 million to the overall revenue growth in the quarter. For the first six months of fiscal 2017, Food Safety revenues increased 11% and Animal Safety revenues increased 14%, each compared to the same period in the prior fiscal year. Overall organic sales increased 5% for the year to date period; the organic increases were 9% for the Food Safety segment and 2% for the Animal Safety segment. Lab M (August 2015) and the previously mentioned acquisitions contributed $12.1 million to the overall revenue growth in the first six months of fiscal 2017. In the first quarter of fiscal 2017, the Company lost the ability to sell its popular canine thyroid replacement product after the FDA approved a new drug application for a competitor, which gave the competitor exclusive marketing rights to the product. The Company will be unable to sell this product, which had sales of $6.6 million for the full 2016 fiscal year, in the U.S. until similar regulatory approval is granted; the Company does not expect that this approval will occur in the current fiscal year. Excluding the impact of the loss of revenues of this product and adverse currency translations, primarily due to the devaluation of the pound sterling and the Mexican peso, overall organic sales growth would have been 11% for both the second quarter and year to date periods.

International sales were $31.2 million in the second quarter, an increase of 9% compared to the prior year. Expressed as a percentage of total sales, international sales were 34.4% compared to 36.0% in the second quarter of the prior year. For the six month period, international sales were $60.3 million, an increase of 13%; international sales were 34.6% of total sales in the current year to date period and 34.4% in the prior year. Currency translations had an adverse effect of approximately $2.1 million on international revenue in the second quarter and $4.0 million for the year to date.

Neogen Europe, based in Ayr, Scotland, recorded sales increases of 33% in its local currency, the pound sterling, in the second quarter; this increase was reduced to 10% when these revenues were translated to U.S. dollars. For the six month period, revenues increased 38% in pound sterling, which was reduced to a 17% increase when translated to dollars. Strong sales of deoxynivalenol (DON) test kits, due to outbreaks of contaminated corn crops in western Europe, and increases in genomics revenues resulting from the addition of an in-house genomics lab in Ayr, led the growth at the Company’s European subsidiary for both the second quarter and year to date periods.

Neogen do Brasil recorded an increase of 64% in its local currency, the real, in the second quarter. The Company benefitted from favorable currency conditions as the real strengthened during the quarter, resulting in a 93% revenue increase when translated to U.S. dollars. For the year to date period, revenues increased 54% in local currency and 66% in dollars. For both periods, the increase was led by sales of forensic test kits, sold to testing labs in Brazil for drug testing of commercial truck drivers, and sales of the Company’s Acumedia line of dehydrated culture media as the subsidiary recorded market share gains. The Company’s Mexico-based subsidiary recorded an increase of 3% in its local currency, the peso, which was reduced to an 11% decrease when translated to U.S. dollars, for the second quarter. The peso declined 10% in early November following the results of the U.S. presidential election. For the six month period, Neogen Latinoamerica sales increased 20% in pesos and 4% after translating to dollars. The lower 3% growth rate in the second quarter was primarily due to delays in order timing for several customers.

Service revenue was $13.8 million for the quarter ended November 30, 2016, an increase of $2.9 million, or 26%, compared to the same quarter in the prior year. For the year to date period, service revenue increased 21%, from $20.7 million in the prior year to $25.2 million in fiscal 2017. For both the second quarter and year to date periods, the growth was led by increased genomics revenues, the result of additional business with a large customer in the poultry market, custom research work, and increased sales to the bovine market.

Gross margin was 48.1% in the second quarter of fiscal 2017 compared to 48.0% in the same period a year ago. Favorable product mix in the quarter, led by strong sales of DON test kits, forensic test kits and rodenticides, offset the lower margin impact of the recent Lab M and Preserve/Tetradyne acquisitions, the loss of the high margin thyroid replacement product and the negative impact of currency

translations. For the six-month period, gross margin was 48.2% compared to 49.2% in the prior year. On a year to date basis, the loss of the thyroid replacement product lowered gross margin by approximately 60 basis points in the current year; adverse currency translations and product mix also negatively impacted gross margins.

Total operating expenses increased 13% for both the quarter and year to date periods. Sales and marketing expense increased $1.5 million in the second quarter and $2.7 million for the six month period; each period represented a 10% increase over the same period in the prior year. The largest increases for both the quarter and year to date were commissions, shipping and royalties, all of which are based on the revenue increase, and higher salaries, the result of increased staffing and compensation increases. General and administrative expense increased $1.5 million in the quarter and $3.0 million for the year to date; each increased 22% compared to the same periods in the prior year. Recent acquisitions contributed $1.4 million of the increase year to date, with half of that in the second quarter. Additional increases were for personnel related expenditures, and higher depreciation on information technology equipment and software. Research and development expense increased $150,000, or 6%, in the second quarter and rose $254,000, or 5%, for the six months, and reflect continued investment in product improvement and development, primarily in the Food Safety segment.

Operating income was $16.9 million for the second quarter of fiscal 2017, an increase of 15%, from $14.6 million recorded in last year’s second quarter. Expressed as a percentage of revenue, operating income was 18.6%, compared to 18.4% for the same period in the prior year. The increase in operating margin was due to the slight improvement in gross margin and operating expenses that rose less than the increase in revenues. For the six month period, operating income was $31.6 million, or 18.1% of sales, compared to $29.5 million, or 19.1% of sales, in the same period of the prior year. The decline in operating margin, as a percentage of revenues, on a year to date basis is due to the decrease in gross margin percentage, which resulted from the loss of the thyroid replacement product, adverse currency translations and product mix.

Other expense in the second quarter of fiscal 2017 was $81,000 compared to expense of $420,000 in the prior year. Currency loss of $424,000 was offset by royalty income of $22,000 and interest income of $296,000. The increase in interest income for the quarter was due to interest received on funds on deposit in Brazil; the approximate annual interest rate in Brazil is 14%. In the second quarter of the prior year, currency loss was $562,000, partially offset by interest income of $51,000 and royalty income of $67,000. For the first six months of fiscal 2017, other income was $412,000, comprised primarily of interest income of $420,000 and royalty income of $67,000, offset by currency loss of $178,000. For the year to date period in the prior year, other expense of $876,000 includes currency loss of $1,167,000, interest income of $119,000 and royalty income of $109,000.

The Company’s effective tax rate in the second quarter was 33.4% compared to 35.6% in the prior year. The current year provision includes a tax credit for research and development; this was not recorded in last year’s second quarter as the credit had not yet been approved by the U.S. Congress. For the year to date period, the effective tax rate was 34.1% compared to 35.6% in the prior year. Net income attributable to Neogen increased $2.1 million, or 23%, for the second quarter of fiscal 2017 and $2.6 million, or 14%, for the six month period, each compared to the same period in the prior year.

Revenues


	Three Months ended November 30,
	2016		2015		Increase/ (Decrease)			%
			(in thousands)
Food Safety
Natural Toxins, Allergens & Drug Residues	$	19,030	$	16,409	$	2,621			16.0	%
Bacterial & General Sanitation		8,429		8,495		(66	)		-0.8	%
Dehydrated Culture Media & Other		13,302		12,350		952			7.7	%

	$	40,761	$	37,254	$	3,507			9.4	%
Animal Safety
Life Sciences	$	2,674	$	1,960	$	714			36.4	%
Veterinary Instruments & Disposables		9,649		10,411		(762	)		-7.3	%
Animal Care & Other		8,468		9,870		(1,402	)		-14.2	%
Rodenticides, Insecticides & Disinfectants		19,004		11,912		7,092			59.5	%
DNA Testing Service		10,161		8,203		1,958			23.9	%

	$	49,956	$	42,356	$	7,600			17.9	%

Total Revenues	$	90,717	$	79,610	$	11,107			14.0	%


	Six Months ended November 30,
	2016		2015		Increase/ (Decrease)			%
			(in thousands)
Food Safety
Natural Toxins, Allergens & Drug Residues	$	36,637	$	32,792	$	3,845			11.7	%
Bacterial & General Sanitation		16,992		16,571		421			2.5	%
Dehydrated Culture Media & Other		26,135		22,351		3,784			16.9	%

	$	79,764	$	71,714	$	8,050			11.2	%
Animal Safety
Life Sciences	$	4,929	$	3,659	$	1,270			34.7	%
Veterinary Instruments & Disposables		19,281		20,578		(1,297	)		-6.3	%
Animal Care & Other		15,605		18,028		(2,423	)		-13.4	%
Rodenticides, Insecticides & Disinfectants		36,685		25,037		11,648			46.5	%
DNA Testing Service		18,098		15,455		2,643			17.1	%

	$	94,598	$	82,757	$	11,841			14.3	%

Total Revenues	$	174,362	$	154,471	$	19,891			12.9	%

The Company’s Food Safety segment revenues were $40.8 million in the quarter ended November 30, 2016, an increase of 9% compared to the same period in the prior year. For the six month period, Food Safety revenues increased 11% to $79.8 million. Organic growth for the segment was 8% for the quarter and 9% for the year to date period, with the acquisitions of Lab M on August 26, 2015 and Deoxi on April 26, 2016 contributing the remainder of growth. Adverse currency translations, resulting from the strength of the U.S. dollar, reduced both overall segment growth and organic growth for both periods. In a neutral currency environment, Food Safety growth was 15% for the second quarter of fiscal 2017, with organic growth of 14%; year to date, the overall increase was 17% and organic growth was 14%.

Natural Toxins, Allergens & Drug Residues sales increased 16% in the second quarter and 12% for the first six months of fiscal 2017. For the second quarter, sales of natural toxins increased 27%, led by sales of DON test kits and related equipment due to outbreaks of DON in corn crops in the Midwest U.S., Canada and Europe; overall sales of this product line have risen 14% for the year to date period. Allergen

test kit revenues rose 20% in the quarter and 18% for the six month period, as increased consumer awareness and recalls relating to allergenic contamination of food continues to expand the market. Sales of test kits to detect the presence of drug residues, primarily in dairy milk, were down 8% in the quarter, due in large part to order timing from a large distributor and market losses in Europe; sales of these kits were flat for the year to date period.

Sales of Bacterial & General Sanitation products decreased 1% in the second quarter but rose 3% for the year to date. For the quarter, sales of Salmonella test kits increased 18%; this increase was offset by a 24% decline in sales of Listeria test kits, due to a research project in the prior year which did not recur, and an 18% decrease in sales of Soleris and BioLumix equipment, due to difficult comparisons to a strong prior year quarter. For the six month period, sales of Salmonella test kits increased 14% and the Company’s AccuPoint sanitation monitoring product line rose 5%, while Listeria test kit sales recorded an 8% decline.

Dehydrated Culture Media & Other increased 8% in the second quarter and 17% for the year to date period, each compared to the same periods a year ago, aided in part by the acquisitions of Lab M and Deoxi. Organic growth was 4% and 8% for the quarter and year to date periods, respectively. Genomics revenue, which is reported in the Other category in the Food Safety segment, increased 70% for the quarter and 78% for the six months, due primarily to the transfer of certain genomics revenues from GeneSeek to Neogen Europe as the Ayr, Scotland based operation added genomics testing capabilities to better serve the growing European market. Partially offsetting this was a 15% decrease in sales of the Company’s Acumedia line of dehydrated culture media sold into traditional domestic media markets; the prior year had strong sales resulting from a customer’s research project which did not recur; this resulted in a 28% decline for the six month period.

The Company’s Animal Safety segment revenues were $50.0 million, an increase of 18% compared to the same quarter in the prior year. Organic growth for the segment was 5% for the quarter and 2% for the year to date period, with the acquisitions of Virbac on December 22, 2015 and Preserve/Tetradyne on May 1, 2016 contributing the remainder of growth. Revenues for the six month period increased 14% to $94.6 million from $82.8 million in the prior year. Excluding the loss of the previously discussed thyroid replacement product, this segment had overall organic growth of 9% for the second quarter and 7% for the year to date period. Currency translations had minimal effect on revenues in this segment.

Life Sciences sales increased 36% for the second quarter and 35% for the year to date period, each compared to the prior year, the result of increased volume from testing labs to meet new requirements for drug testing of commercial truck drivers in Brazil. Sales of Veterinary Instruments & Disposables products were down 7% for the quarter and 6% for the year to date. In the second quarter, decreases in disposable syringes, which had increased sales in the prior year due to a competitor’s backorder situation, and marking products were partially offset by a 19% increase in detectable needles, with particularly strong sales to international customers.

Animal Care & Other sales decreased 14% in the quarter ended November 30, 2016 and year to date sales decreased 13%. The decrease is due to the loss of the ability to sell the Company’s popular thyroid replacement product; the decrease was $1.4 million in the second quarter and $4.4 million for the first six months of the fiscal year. Partially offsetting this decline was an increase in sales of vitamin injectables due to a marketing program in the second quarter.

Rodenticides, Insecticides & Disinfectants sales increased 60% in the second quarter and 47% for the six month period, each compared to the same periods in the prior year. Organic growth in this category was 14% for the quarter and 6% for the year to date. In the second quarter, the Preserve/Tetradyne acquisition added $5.2 million of cleaner and disinfectant sales, primarily to domestic swine, poultry, dairy and food processing markets; year to date sales were $9.7 million. Rodenticide sales increased 16% for both the three and six month periods, led by incremental revenues from contract manufacturing agreements and continued penetration of the retail agricultural market, and partially offset by a decline in sales to the northwest U.S. resulting from strong sales in the prior year due to a rodent outbreak which moderated in the current year. Cleaner and disinfectant sales increased 13% on an organic basis for the quarter, led by increases in international markets; year to date sales are down 7% due primarily to weak demand in international markets in the first quarter. Chem-Tech revenues increased 22% in the quarter and 7% for the six months due to timing of distributor orders of insecticides.

DNA Testing revenues reported within the Animal Safety segment increased 24% in the second quarter of fiscal 2017 and were up 17% for the six month period. The increase for the quarter was due to significant research projects with two universities and continued new business with a large customer in the poultry market. In the third quarter of fiscal 2016, the Company began processing genomic samples at its Neogen Europe location after expanding its genomic laboratory capabilities. Neogen Europe reports through the Food Safety segment and recorded approximately $800,000 of revenues in each of the first two quarters that would have been reported through this product line in the prior year. Overall, DNA testing revenues rose 31% worldwide in the quarter and 26% year to date compared to the same periods last year.

Financial Condition and Liquidity

The overall cash, cash equivalents and marketable securities position of the Company was $142.1 million at November 30, 2016, compared to $107.8 million at May 31, 2016. Approximately $29.5 million was generated from operations during the first six months of fiscal 2017. Net cash proceeds of $10.3 million were realized from the exercise of stock options and issuance of shares under the Company’s employee stock purchase plan during the same period. The Company spent $6.2 million for property, equipment and other non-current assets in the first half of fiscal 2017.

Accounts receivable balances were $64.9 million at November 30, 2016, a decline of $2.8 million, or 4%, compared to $67.7 million at May 31, 2016. Average days’ sales outstanding was 63 days at November 30, 2016, compared to 61 days at May 31, 2016. Inventory levels rose by $7.3 million, or 11%, compared to May 31, 2016. The increase is due primarily to the timing of receipts of orders and planned increases in stocking levels of identified key products to ensure availability and improve service levels.

Inflation and changing prices are not expected to have a material effect on operations, as management believes it will continue to be successful in offsetting increased input costs with price increases and/or cost efficiencies.

Management believes that the Company’s existing cash and marketable securities balances at November 30, 2016, along with available borrowings under its credit facility and cash expected to be generated from future operations, will be sufficient to fund activities for the foreseeable future. However, existing cash and borrowing capacity may not be sufficient to meet the Company’s cash requirements to commercialize products currently under development or its plans to acquire other organizations, technologies or products that fit within the Company’s mission statement. Accordingly, the Company may choose to issue equity securities or enter into other financing arrangements for a portion of its future financing needs.

PART I – FINANCIAL INFORMATION

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company has interest rate and foreign exchange rate risk exposure but no long-term fixed rate investments or borrowings. The Company’s primary interest rate risk is due to potential fluctuations of interest rates for variable rate borrowings (no borrowings at November 30, 2016) and short-term investments.

Foreign exchange risk exposure arises because the Company markets and sells its products throughout the world. Revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. dollar. The Company’s operating results are exposed to changes in exchange rates between the U.S. dollar and the British pound sterling, the euro, the Mexican peso, the Brazilian real, the Chinese yuan, and to a lesser extent, the Indian rupee and the Canadian dollar. When the U.S. dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. Additionally, previously recognized revenues in the course of collection can be affected positively or negatively by changes in exchange rates. The Company uses derivative financial instruments to help manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.

Neogen has assets, liabilities and operations outside of the United States, located in Scotland, England, Brazil, Mexico, China, India, and Canada where the functional currency is the British pound sterling, Brazilian real, Mexican peso, Chinese yuan, Indian rupee and Canadian dollar, respectively, and also transacts business throughout Europe in the euro. The Company’s investments in foreign subsidiaries are considered to be long-term.

PART I – FINANCIAL INFORMATION

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of November 30, 2016 was carried out under the supervision and with the participation of the Company’s management, including the Chairman & Chief Executive Officer and the Vice President & Chief Financial Officer (“the Certifying Officers”). Based on the evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures are effective.

Changes in Internal Controls over Financial Reporting

No changes in our control over financial reporting were identified as having occurred during the quarter ended November 30, 2016 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

The Company is subject to certain legal and other proceedings in the normal course of business. In the opinion of management, the outcomes of these matters are not expected to have a material effect on its future results of operations or financial position.

Item 6. Exhibits

(a) Exhibit Index


31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a).

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a).

32		Certification pursuant to 18 U.S.C. section 1350

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Items 1A, 2, 3, 4, and 5 are not applicable or removed or reserved and have been omitted.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NEOGEN CORPORATION

(Registrant)

Dated: December 29, 2016

/s/ James L. Herbert

James L. Herbert

Chairman & Chief Executive Officer

(Principal Executive Officer)

Dated: December 29, 2016

/s/ Steven J. Quinlan

Steven J. Quinlan

Vice President & Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 d298040dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

13a. – CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

NEOGEN CORPORATION AND SUBSIDIARIES

CEO CERTIFICATION

I, James L. Herbert, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the period ended November 30, 2016 of Neogen Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrant’s auditors and the audit committee of registrant’s board of directors:

all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: December 29, 2016

/s/ James L. Herbert

James L. Herbert

Chairman & Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d298040dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

13a. – CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

NEOGEN CORPORATION AND SUBSIDIARIES

CFO CERTIFICATION

I, Steven J. Quinlan, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the period ended November 30, 2016 of Neogen Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrant’s auditors and the audit committee of registrant’s board of directors:

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: December 29, 2016

/s/ Steven J. Quinlan

Steven J. Quinlan

Vice President & Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

EX-32 4 d298040dex32.htm EX-32 EX-32

EXHIBIT 32

18 U.S.C. SECTION 1350 CERTIFICATION

NEOGEN CORPORATION

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Neogen Corporation (the “Company”) for the period ended November 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James L. Herbert, as Chief Executive Officer of the Company and I, Steven J. Quinlan, as Chief Financial Officer, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

This Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

Information contained in this Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: December 29, 2016

/s/ James. L. Herbert

James L. Herbert

Chairman & Chief Executive Officer

(Principal Executive Officer)

/s/ Steven J. Quinlan

Steven J. Quinlan

Vice President & Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 neog-20161130.xml XBRL INSTANCE DOCUMENT

1125000

780000

155000

48000

159000

421000

499000

2090000

178000

453000

266000

2552000

232000

9000

89000

132000

350000

193000

660000

868000

1625000

269000

1964000

1629000

10590000

948000

784000

3337000

285000

309000

1169000

975000

3611000

64000

525000

422000

300000

60000

317000

2545000

12000000

71378000

425783000

182478000

132472000

110833000

60000000

37970778

0.16

37970778

0.0177

2252000

42.83

100000

1.00

1012974

273165000

52538000

487311000

4442000

-8130000

916000

17287000

434737000

15000000

6076000

163626000

2251000

16418000

1650000

1383000

434773000

10757000

36000

33869000

60000

288401000

5588000

55533000

86297000

1748000

71683000

64902000

55809000

487311000

87581000

31881000

34214000

9370000

7962000

217572000

142303000

127436000

273165000

163626000

36000

-8130000

37970778

6076000

18186000

27271000

9768000

19155000

66061000

102000

141000

14000

43000

345000

60000000

37567689

0.16

37567689

2081000

36.71

100000

1.00

252133000

47554000

451715000

4986000

-3946000

916000

15800000

404198000

6011000

150000000

2423000

16533000

1500000

404161000

7812000

-37000

28598000

60000

250001000

4498000

54683000

55257000

1775000

64371000

67652000

52539000

451715000

88506000

29501000

30372000

9170000

8407000

252133000

150000000

-37000

-3946000

37567689

6011000

17277000

30909000

7530000

18446000

4514000

P15Y

P5Y

1549000

P10Y

P5Y

24086000

P15Y

P5Y

12436000

P15Y

P5Y

2040000

P15Y

P5Y

3525000

P15Y

P5Y

2017-09-01

20500000

13000000

1118000

P15Y

P5Y

0.49

20861000

37810000

37301000

0.49

509000

154471000

13554000

2443000

133754000

20717000

83916000

7815000

29507000

18396000

8784000

-2514000

17424000

17389000

18431000

-1007000

119000

76016000

-995000

-876000

1858000

28631000

5680000

308000

10200000

-24906000

2545000

2443000

80379000

27774000

13543000

9054000

35000

5192000

5317000

35000

64637000

78455000

13818000

4776000

46509000

6611000

82757000

67021000

15736000

15173000

71714000

66733000

4981000

16108000

-1774000

<div> 9. COMMITMENTS AND CONTINGENCIES The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company expenses annual costs of remediation, which have ranged from $47,000 to $57,000 per year over the past five years. The Company’s estimated liability for these costs is $916,000 at November 30, 2016 and May 31, 2016, measured on an undiscounted basis over an estimated period of 15 years; $60,000 of the liability is recorded within current liabilities and the remainder is recorded within other long-term liabilities in the consolidated balance sheet. The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position. </div>

Q2 2017 10-Q

0.55

0000711377

<div> 2. INVENTORIES Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories follow:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> November 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> May 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Raw Materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,881</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Work-in-process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,588</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,498</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finished and purchased goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34,214</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,372</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">71,683</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">64,371</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

LIBOR plus 100 basis points

29549000

<div> 6. NEW ACCOUNTING PRONOUNCEMENTS In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers. The new standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. In April 2016, the FASB issued Accounting Standards Update No. 2016-10— Revenue from Contracts with Customers (Topic 606), which amends and adds clarity to certain aspects of the guidance set forth in ASU 2014-09 related to identifying performance obligations and licensing. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is not permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11—Inventory: Simplifying the Measurement of Inventory. The update requires inventory not measured using either the last in, first out (LIFO) or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal and transportation. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company is currently evaluating the impact of ASU 2015-11 on its consolidated financial condition and results of operations.   In September 2015, the FASB issued ASU 2015-16—Simplifying the Accounting for Measurement - Period Adjustments. Changes to the accounting for measurement-period adjustments relate to business combinations. Currently, an acquiring entity is required to retrospectively adjust the balance sheet amounts of the acquiree recognized at the acquisition date with a corresponding adjustment to goodwill as a result of changes made to the balance sheet amounts of the acquiree. The measurement period is the period after the acquisition date during which the acquirer may adjust the balance sheet amounts recognized for a business combination (generally up to one year from the date of acquisition). The changes eliminate the requirement to make such retrospective adjustments, and instead require the acquiring entity to record these adjustments in the reporting period they are determined. The new standard is effective for public companies for fiscal years beginning after December 15, 2015. The Company has adopted this standard, which does not have a material impact on its consolidated financial condition and results of operations. The FASB recently issued ASU No. 2015-17—Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes as part of its Simplification Initiative. The amendments eliminate the guidance in Topic 740, Income Taxes, that required an entity to separate deferred tax liabilities and assets between current and noncurrent amounts in a classified balance sheet. Rather, deferred taxes will be presented as noncurrent under the new standard. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017 for public companies. Early adoption is permitted. The Company does not believe that adoption of this standard will have a material impact on its consolidated financial condition. In February 2016, the FASB issued ASU No. 2016-02—Leases to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The recognition, measurement and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous U.S. GAAP. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018. Modified retrospective application is permitted with certain practical expedients. Early adoption is permitted. The Company is currently evaluating the impact of ASU No. 2016-02 on its consolidated financial condition and results of operations. In March 2016, the FASB issued ASU No. 2016-09 — Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting to provide guidance that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid-in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 with early adoption permitted. The Company is currently evaluating the impact of ASU No. 2016-09 on its consolidated financial condition and results of operations. In August 2016, the FASB issued ASU No. 2016-15— Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force). The amendments in ASU 2016-15 address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows under FASB Accounting Standards Codification (FASB ASC) 230, Statement of Cash Flows. The amendments in ASU 2016-15 are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption during an interim period. The Company has not yet adopted this update and is currently evaluating the impact of ASU No. 2016-15 on its consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16 — Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory which requires companies to account for income tax effects of intercompany transactions other than inventory in the period in which the transfer occurs. This is a change from current GAAP, which requires companies to defer the income tax effects of intercompany transfers of assets until the asset has been sold to an outside party or otherwise recognized (i.e. depreciation, amortization, impaired). ASU 2016-16 will still require companies to defer the income tax effects of intercompany inventory transactions. The amendments of this ASU are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. The Company has not yet adopted this update and is currently evaluating the impact of ASU No. 2016-16 on its consolidated financial statements. </div>

28.21

NEOG

38183000

37715000

false

<div> 1. BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the six month period ended November 30, 2016 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2017. For more complete financial information, these consolidated financial statements should be read in conjunction with the May 31, 2016 audited consolidated financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended May 31, 2016. </div>

<div> The calculation of net income per share attributable to Neogen Corporation follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> November 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> November 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in thousands, except per share amounts)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Numerator for basic and diluted net income per share- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income attributable to Neogen </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,151</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,073</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,032</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,396</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Denominator for basic net income per share- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,390</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,715</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,301</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Effect of dilutive stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">446</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">478</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">468</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">509</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Denominator for diluted net income per share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,262</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,868</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,183</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,810</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net income attributable to Neogen per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.29</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.24</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.29</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.24</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.55</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The components of inventories follow:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> November 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> May 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Raw Materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,881</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,501</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Work-in-process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,588</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,498</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finished and purchased goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34,214</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,372</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">71,683</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">64,371</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

33000

40.84

53.99

<div> 10. STOCK PURCHASE The Company has a stock repurchase program, authorized by the Board of Directors in calendar year 2008, to purchase, subject to market conditions, up to 1,125,000 shares of the Company’s common stock. As of November 30, 2016, 1,012,974 shares are available to be repurchased under the program. There were no purchases in fiscal year 2016 and there have been none thus far in fiscal 2017. </div>

--05-31 2016-11-30

0.56

Large Accelerated Filer

468000

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Segment information follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate and</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Food</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Animal</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Eliminations</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Safety</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Safety</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> As of and for the three months ended November 30,  2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Product revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,279</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,682</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">76,961</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Service revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,482</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,274</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,756</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,956</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">90,717</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,979</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,998</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,125</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,852</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">142,303</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">217,572</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">127,436</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">487,311</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> As of and for the three months ended November 30,  2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Product revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,682</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,035</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,717</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Service revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,572</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,321</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,893</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,254</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,356</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79,610</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,687</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,833</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(908</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,612</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132,472</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">182,478</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110,833</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">425,783</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate and</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Food</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Animal</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Eliminations</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Safety</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Safety</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> For the six months ended November 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Product revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">72,921</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">76,285</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">149,206</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Service revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,843</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,313</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,156</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79,764</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">94,598</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">174,362</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,062</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,694</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,162</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31,594</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> For the six months ended November 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Product revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">66,733</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">67,021</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">133,754</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Service revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,981</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,736</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20,717</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71,714</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">82,757</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">154,471</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,173</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,774</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,507</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.</td> </tr> </table> </div>

<div> A summary of stock option activity during the six months ended November 30, 2016 follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Weighted-</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Average</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Exercise Price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding June 1, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,081,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36.71</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">607,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53.99</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(403,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28.21</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(33,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40.84</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding November 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,252,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42.83</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> The fair value of stock options granted was estimated using the following weighted-average assumptions.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">FY2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">FY2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected stock price volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35.2</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33.3</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected option life </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.0 years</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.0 years</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

607000

403000

2019-09-30

<div> 3. NET INCOME PER SHARE The calculation of net income per share attributable to Neogen Corporation follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> November 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> November 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in thousands, except per share amounts)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Numerator for basic and diluted net income per share- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net income attributable to Neogen </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,151</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,073</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,032</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,396</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Denominator for basic net income per share- </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted average shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,816</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,390</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,715</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,301</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Effect of dilutive stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">446</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">478</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">468</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">509</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Denominator for diluted net income per share </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,262</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,868</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,183</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,810</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net income attributable to Neogen per share: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Basic </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.29</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.24</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Diluted </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.29</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.24</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.55</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

NEOGEN CORP

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> 4. SEGMENT INFORMATION <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors; this segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> These segments are managed separately because they represent strategic business units that offer different products and require different marketing strategies. The Company evaluates performance based on total sales and operating income of the respective segments. The accounting policies of each of the segments are the same as those described in Note 1. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Segment information follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate and</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Food</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Animal</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Eliminations</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Safety</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Safety</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> As of and for the three months ended November 30,  2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Product revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37,279</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,682</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">76,961</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Service revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,482</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,274</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,756</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,956</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">90,717</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,979</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,998</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,125</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,852</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">142,303</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">217,572</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">127,436</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">487,311</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> As of and for the three months ended November 30,  2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Product revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,682</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,035</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,717</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Service revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,572</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,321</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,893</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,254</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,356</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79,610</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,687</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,833</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(908</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,612</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132,472</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">182,478</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">110,833</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">425,783</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate and</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Food</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Animal</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Eliminations</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Safety</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Safety</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">(1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="14" align="center">(in thousands)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> For the six months ended November 30, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Product revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">72,921</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">76,285</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">149,206</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Service revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,843</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,313</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,156</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Total revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">79,764</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">94,598</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">174,362</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,062</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,694</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,162</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31,594</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> For the six months ended November 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Product revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">66,733</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">67,021</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">133,754</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Service revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,981</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,736</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20,717</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Total revenues to external customers </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71,714</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">82,757</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">154,471</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,108</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,173</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,774</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,507</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.</td> </tr> </table> </div>

174362000

437000

2476000

13263000

428000

149206000

25156000

67792000

6238000

31594000

21032000

7963000

-1847000

16921000

16848000

21105000

-4184000

419000

84070000

-8000

-4184000

411000

-428000

32005000

2476000

7038000

-1385000

10900000

-9945000

2734000

2476000

64522000

30484000

16546000

12821000

73000

5446000

31040000

73000

74425000

90292000

15867000

6836000

52476000

10345000

P5Y P15Y

0.0100

0.05

94598000

76285000

18313000

16694000

79764000

72921000

6843000

17062000

-2162000

21032000

13199000

427000

73000

-4184000

9000

394000

64000

1000

P5Y

57000

P10Y

P3Y

47000

P5Y 70000

P4Y

0.000

0.012

13.11

0.333

P4Y

0.000

0.012

15.79

0.352

0.29

38262000

37816000

0.29

446000

90717000

76961000

13756000

16852000

11151000

9565000

9545000

11171000

-1606000

296000

43591000

-377000

-81000

16771000

5600000

1218000

15687000

8284000

20000

2768000

20000

38890000

47126000

8236000

26739000

49956000

39682000

10274000

8998000

40761000

37279000

3482000

8979000

-1125000

0.24

37868000

37390000

0.24

478000

79610000

68717000

10893000

14612000

9073000

8848000

8779000

9142000

-294000

51000

38224000

-471000

-420000

14192000

5050000

1248000

14203000

6791000

69000

2618000

69000

34006000

41386000

7380000

23612000

42356000

34035000

8321000

7833000

37254000

34682000

2572000

7687000

-908000

0000711377 neog:CorporateAndIntersegmentEliminationsMember 2015-08-27 2015-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:FoodSafetyMember 2015-08-27 2015-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:AnimalSafetyMember 2015-08-27 2015-11-30 0000711377 2015-08-27 2015-11-30 0000711377 neog:CorporateAndIntersegmentEliminationsMember 2016-09-01 2016-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:FoodSafetyMember 2016-09-01 2016-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:AnimalSafetyMember 2016-09-01 2016-11-30 0000711377 2016-09-01 2016-11-30 0000711377 us-gaap:ScenarioForecastMember 2016-06-01 2017-05-31 0000711377 2015-06-02 2016-05-31 0000711377 neog:SterlingTestHouseMember 2016-07-01 2016-07-31 0000711377 us-gaap:MinimumMember 2016-06-01 2016-11-30 0000711377 us-gaap:MaximumMember 2016-06-01 2016-11-30 0000711377 us-gaap:CommonStockMember 2016-06-01 2016-11-30 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-01 2016-11-30 0000711377 us-gaap:NoncontrollingInterestMember 2016-06-01 2016-11-30 0000711377 us-gaap:AdditionalPaidInCapitalMember 2016-06-01 2016-11-30 0000711377 us-gaap:RetainedEarningsMember 2016-06-01 2016-11-30 0000711377 neog:CorporateAndIntersegmentEliminationsMember 2016-06-01 2016-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:FoodSafetyMember 2016-06-01 2016-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:AnimalSafetyMember 2016-06-01 2016-11-30 0000711377 neog:TwoThousandElevenPlanMemberus-gaap:EmployeeStockMember 2016-06-01 2016-11-30 0000711377 neog:UnsecuredRevolvingLineOfCreditMemberneog:LiborPlusMember 2016-06-01 2016-11-30 0000711377 2016-06-01 2016-11-30 0000711377 neog:CorporateAndIntersegmentEliminationsMember 2015-06-02 2015-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:FoodSafetyMember 2015-06-02 2015-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:AnimalSafetyMember 2015-06-02 2015-11-30 0000711377 2015-06-02 2015-11-30 0000711377 neog:SterlingTestHouseMemberus-gaap:MinimumMember 2015-06-01 2015-06-01 0000711377 neog:SterlingTestHouseMemberus-gaap:MaximumMember 2015-06-01 2015-06-01 0000711377 neog:SterlingTestHouseMember 2015-06-01 2015-06-01 0000711377 neog:RogamaIndustriaEComercioLtdaMemberus-gaap:SubsequentEventMember 2016-12-27 2016-12-27 0000711377 neog:QuatChemLtdMemberus-gaap:SubsequentEventMember 2016-12-01 2016-12-01 0000711377 2016-11-29 2016-11-29 0000711377 neog:VirbacCorporationMemberus-gaap:MinimumMember 2015-12-22 2015-12-22 0000711377 neog:VirbacCorporationMemberus-gaap:MaximumMember 2015-12-22 2015-12-22 0000711377 neog:VirbacCorporationMember 2015-12-22 2015-12-22 0000711377 neog:BeijingAnapureBioscientificCoLtdMemberus-gaap:MinimumMember 2014-12-08 2014-12-08 0000711377 neog:BeijingAnapureBioscientificCoLtdMemberus-gaap:MaximumMember 2014-12-08 2014-12-08 0000711377 neog:BeijingAnapureBioscientificCoLtdMember 2014-12-08 2014-12-08 0000711377 neog:LabMHoldingsMemberus-gaap:MinimumMember 2015-08-26 2015-08-26 0000711377 neog:LabMHoldingsMemberus-gaap:MaximumMember 2015-08-26 2015-08-26 0000711377 neog:LabMHoldingsMember 2015-08-26 2015-08-26 0000711377 neog:TetradyneLlcMemberus-gaap:MinimumMember 2016-05-01 2016-05-01 0000711377 neog:TetradyneLlcMemberus-gaap:MaximumMember 2016-05-01 2016-05-01 0000711377 neog:TetradyneLlcMember 2016-05-01 2016-05-01 0000711377 neog:DeoxiBiotecnologiaLtdMemberus-gaap:MinimumMember 2016-04-26 2016-04-26 0000711377 neog:DeoxiBiotecnologiaLtdMemberus-gaap:MaximumMember 2016-04-26 2016-04-26 0000711377 neog:DeoxiBiotecnologiaLtdMember 2016-04-26 2016-04-26 0000711377 neog:BiolumixIncMemberus-gaap:MinimumMember 2014-10-01 2014-10-01 0000711377 neog:BiolumixIncMemberus-gaap:MaximumMember 2014-10-01 2014-10-01 0000711377 neog:BiolumixIncMember 2014-10-01 2014-10-01 0000711377 us-gaap:ScenarioForecastMember 2017-05-31 0000711377 us-gaap:OtherIntangibleAssetsMember 2016-05-31 0000711377 us-gaap:CustomerRelatedIntangibleAssetsMember 2016-05-31 0000711377 us-gaap:CommonStockMember 2016-05-31 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-05-31 0000711377 us-gaap:NoncontrollingInterestMember 2016-05-31 0000711377 us-gaap:AdditionalPaidInCapitalMember 2016-05-31 0000711377 us-gaap:RetainedEarningsMember 2016-05-31 0000711377 2016-05-31 0000711377 neog:SterlingTestHouseMember 2015-06-01 0000711377 2015-06-01 0000711377 us-gaap:OtherIntangibleAssetsMember 2016-11-30 0000711377 us-gaap:CustomerRelatedIntangibleAssetsMember 2016-11-30 0000711377 us-gaap:CommonStockMember 2016-11-30 0000711377 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-11-30 0000711377 us-gaap:NoncontrollingInterestMember 2016-11-30 0000711377 us-gaap:AdditionalPaidInCapitalMember 2016-11-30 0000711377 us-gaap:RetainedEarningsMember 2016-11-30 0000711377 neog:CorporateAndIntersegmentEliminationsMember 2016-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:FoodSafetyMember 2016-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:AnimalSafetyMember 2016-11-30 0000711377 2016-11-30 0000711377 neog:CorporateAndIntersegmentEliminationsMember 2015-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:FoodSafetyMember 2015-11-30 0000711377 us-gaap:OperatingSegmentsMemberneog:AnimalSafetyMember 2015-11-30 0000711377 2015-11-30 0000711377 2016-11-29 0000711377 neog:VirbacCorporationMember 2015-12-22 0000711377 neog:BeijingAnapureBioscientificCoLtdMember 2014-12-08 0000711377 neog:LabMHoldingsMember 2015-08-26 0000711377 neog:TetradyneLlcMember 2016-05-01 0000711377 neog:DeoxiBiotecnologiaLtdMemberus-gaap:TrademarksMember 2016-04-26 0000711377 neog:DeoxiBiotecnologiaLtdMember 2016-04-26 0000711377 neog:BiolumixIncMember 2014-10-01 0000711377 2008-12-31 shares iso4217:USD iso4217:USD shares pure neog:Segment Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

EX-101.SCH 6 neog-20161130.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheet link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheet (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statement of Equity link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Consolidated Statement of Equity (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 109 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Net Income per Share link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Segment Information link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Equity Compensation Plans link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - New Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Business and Product Line Acquisitions link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Long Term Debt link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Stock Purchase link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Net Income per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Segment Information (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Equity Compensation Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Calculation of Net Income Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Segment Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Equity Compensation Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Fair Value of Stock Options Granted, Estimated using Weighted-Average Assumptions (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Business and Product Line Acquisitions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Long Term Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Stock Purchase - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 neog-20161130_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 neog-20161130_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 neog-20161130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Accounts receivable, less allowance of $1,650 and $1,500 Accrual for Environmental Loss Contingencies Estimated liability costs of remediation Accrual for environmental loss contingencies undiscounted estimated period. Accrual For Environmental Loss Contingencies Undiscounted Estimated Period Estimated liability, measurement period, years Accrued Environmental Loss Contingencies, Current Estimated liability costs of remediation, current Accrued Income Taxes, Current Income taxes Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-in Capital Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Exercise of options, share based compensation , income tax benefit Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided from operating activities: Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance Amendment Flag Amendment Flag Animal Safety Animal Safety [Member] Animal Safety Assets Total assets Total Assets Assets [Abstract] Assets Assets, Current Total Current Assets Assets, Current [Abstract] Current Assets Beijing Anapure BioScientific Co, Ltd [Member] Beijing Anapure BioScientific Co, Ltd [Member] Beijing Anapure BioScientific Co., Ltd. BioLumix Inc. [Member] BioLumix Inc. [Member] BioLumix, Inc. Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Contingent consideration potential payment Business Combination Disclosure [Text Block] Business and Product Line Acquisitions Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Purchase price allocation for cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Allocation of purchase price for contingent consideration potential payment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Purchase price allocation for other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Purchase price allocation for prepaid assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Purchase price allocation for accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Purchase price allocation for current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Purchase price allocation for deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Purchase price allocation for non-amortizable trademarks Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Purchase price allocation for intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Purchase price allocation for inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Purchase price allocation for long-term liabilities Business combination recognized identifiable assets acquired and liabilities assumed other receivables. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Receivables Purchase price allocation for other receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Purchase price allocation for land, property and equipment Business Combinations [Abstract] Business Combinations [Abstract] Cash and Cash Equivalents, at Carrying Value Cash And Cash Equivalents At End Of Period Cash And Cash Equivalents At Beginning Of Period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net Increase In Cash and Cash Equivalents Commitments and Contingencies Commitments and Contingencies (note 7) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Table] Commitments and Contingencies Disclosure [Table] Commitments and Contingencies Disclosure [Table] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock [Member] Common Stock Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Ending Balance (in shares) Beginning Balance (in shares) Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.16 par value, 60,000,000 shares authorized 37,970,778 and 37,567,689 shares issued and outstanding at November 30, 2016 and May 31, 2016, respectively. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income attributable to Neogen Corporation Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive (income) loss attributable to non-controlling interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Corporate And Intersegment Eliminations [Member] Corporate And Intersegment Eliminations [Member] Corporate and Eliminations Cost of Goods Sold Cost of product revenues Cost of Revenue Total Cost of Revenues Cost of Revenue [Abstract] Cost of Revenues Cost of Services Cost of service revenues Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Customer-Related Intangible Assets [Member] Customer-based intangibles Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Basis Spread on Variable Rate Unsecured revolving line of credit, spread Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Unsecured revolving line of credit, maturity date Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Deferred Tax Assets, Net of Valuation Allowance, Current Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Deferred Income Taxes Deoxi Biotecnologia Ltd [Member] Deoxi Biotecnologia Ltd [Member] Deoxi Biotecnologia Ltd Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Equity Compensation Plans Disclosure of Repurchase Agreements [Abstract] Disclosure of Repurchase Agreements [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Net Income Attributable to Neogen Per Share Net income attributable to Neogen per share: Earnings Per Share, Basic Basic Earnings Per Share, Basic and Diluted [Abstract] Earnings Per Share, Basic and Diluted [Abstract] Earnings Per Share, Diluted Diluted Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings Per Share [Table] Earnings Per Share [Table] Earnings Per Share [Table] Earnings Per Share [Text Block] Net Income per Share Effect of Exchange Rate on Cash and Cash Equivalents Effect of Exchange Rate on Cash Employee-related Liabilities, Current Accrued compensation Employee Stock [Member] Employee Stock Purchase Plan Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Environmental Remediation Expense Environmental remediation expense Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Excess Tax Benefit from Share-based Compensation, Financing Activities Excess income tax benefit from the exercise of stock options Excess Tax Benefit from Share-based Compensation, Operating Activities Excess income tax benefit from the exercise of stock options Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Net Amortizable intangible assets, net of accumulated amortization Finite-Lived Intangible Asset, Useful Life Finite lived intangible assets, useful life Food Safety Food Safety [Member] Food Safety General and Administrative Expense General and administrative Goodwill Goodwill Gross Profit Gross Margin Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Before Taxes Income Statement [Abstract] Income Statement [Abstract] Income Tax Expense (Benefit) Provision for Income Taxes Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable, accruals and other changes Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventories Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities, net of business acquisitions: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Effect of dilutive stock options Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Inventory, Current [Table] Inventory, Current [Table] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventories Inventory, Finished Goods, Net of Reserves Finished and purchased goods Inventory [Line Items] Inventory [Line Items] Inventory, Net Inventories Inventories Inventory, Raw Materials, Net of Reserves Raw Materials Inventory, Work in Process, Net of Reserves Work-in-process Investment Income, Interest Interest income Lab M Holdings [Member] Lab M Holdings [Member] Lab M Holdings Legal Entity [Axis] Legal Entity [Axis] Liabilities Total Liabilities Liabilities and Equity Total Liabilities and Equity Liabilities and Equity [Abstract] Liabilities and Equity Liabilities, Current Total Current Liabilities Liabilities, Current [Abstract] Current Liabilities Libor Plus [Member] Libor Plus [Member] Libor Plus Long-term Line of Credit Unsecured revolving line of credit, advances Line of Credit Facility, Interest Rate at Period End Unsecured revolving line of credit, interest rate Line of Credit Facility, Interest Rate Description Unsecured revolving line of credit, interest terms Line of Credit Facility, Maximum Amount Outstanding During Period Unsecured revolving line of credit, balance outstanding Line of Credit Facility, Maximum Borrowing Capacity Unsecured revolving line of credit, total amount available Long-term Debt [Text Block] Long Term Debt Marketable Securities, Current Marketable securities (at fair value, which approximates cost) Maximum [Member] Maximum Minimum [Member] Minimum Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interest Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash From Financing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash Flows From Financing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Cash Used In Investing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash Flows Used In Investing Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash From Operating Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash Flows From Operating Activities Net Income (Loss) Attributable to Parent Numerator for basic and diluted net income per share - Net income attributable to Neogen Net Income Attributable to Neogen Net Income (Loss) Attributable to Noncontrolling Interest Net (Income) Loss Attributable to Non-Controlling Interest New Accounting Pronouncements and Changes in Accounting Principles [Text Block] New Accounting Pronouncements Noncontrolling Interest [Member] Non-controlling Interest Nonoperating Income (Expense) Total Other Income (Expense) Nonoperating Income (Expense) [Abstract] Other Income (Expense) Number of Reportable Segments Number of reportable segments Operating Expenses Total Operating Expenses Operating Expenses [Abstract] Operating Expenses Operating Income (Loss) Operating income (loss) Operating Income Operating Segments [Member] Operating Segments Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation Other Accrued Liabilities, Current Other accruals Other Assets, Noncurrent [Abstract] Other Assets Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other comprehensive income (loss), net of tax: currency translation adjustments Other Comprehensive Income (Loss), Net of Tax Other comprehensive loss Other Indefinite-lived Intangible Assets Other non-amortizable intangible assets Other Intangible Assets [Member] Other Intangible Assets Other Long-term Debt, Noncurrent Other Long-Term Liabilities Other Nonoperating Income (Expense) Other income (expense) Payment for business acquisition contingent consideration. Payment For Business Acquisition Contingent Consideration Cash paid for contingent consideration Payments to Acquire Businesses, Gross Cash consideration for purchase of business Payments to Acquire Businesses, Net of Cash Acquired Business acquisitions, net of cash acquired Payments to Acquire Marketable Securities Purchases of marketable securities Payments to Acquire Productive Assets Purchases of property, equipment and other non-current intangible assets Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Value, Issued Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets EX-101.PRE 10 neog-20161130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	6 Months Ended
Document and Entity Information	Nov. 30, 2016 shares
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Nov. 30, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	NEOG
Entity Registrant Name	NEOGEN CORP
Entity Central Index Key	0000711377
Current Fiscal Year End Date	--05-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	37,970,778

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheet - USD ($) $ in Thousands	Nov. 30, 2016	May 31, 2016
Current Assets
Cash and cash equivalents	$ 86,297	$ 55,257
Marketable securities (at fair value, which approximates cost)	55,809	52,539
Accounts receivable, less allowance of $1,650 and $1,500	64,902	67,652
Inventories	71,683	64,371
Deferred income taxes	1,748	1,775
Prepaid expenses and other current assets	7,962	8,407
Total Current Assets	288,401	250,001
Net Property and Equipment	55,533	54,683
Other Assets
Goodwill	87,581	88,506
Other non-amortizable intangible assets	9,370	9,170
Total Assets	487,311	451,715
Current Liabilities
Accounts payable	17,287	15,800
Accrued compensation	4,442	4,986
Income taxes	1,383
Other accruals	10,757	7,812
Total Current Liabilities	33,869	28,598
Deferred Income Taxes	16,418	16,533
Other Long-Term Liabilities	2,251	2,423
Total Liabilities	52,538	47,554
Commitments and Contingencies (note 7)
Equity
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding
Common stock, $0.16 par value, 60,000,000 shares authorized 37,970,778 and 37,567,689 shares issued and outstanding at November 30, 2016 and May 31, 2016, respectively.	6,076	6,011
Additional paid-in capital	163,626	150,000
Accumulated other comprehensive loss	(8,130)	(3,946)
Retained earnings	273,165	252,133
Total Neogen Corporation Stockholders' Equity	434,737	404,198
Non-controlling interest	36	(37)
Total Equity	434,773	404,161
Total Liabilities and Equity	487,311	451,715
Customer-based intangibles
Other Assets
Amortizable intangible assets, net of accumulated amortization	27,271	30,909
Other Intangible Assets
Other Assets
Amortizable intangible assets, net of accumulated amortization	$ 19,155	$ 18,446

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands	Nov. 30, 2016	May 31, 2016
Accounts receivable, allowance	$ 1,650	$ 1,500
Preferred stock, par value	$ 1.00	$ 1.00
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.16	$ 0.16
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	37,970,778	37,567,689
Common stock, shares outstanding	37,970,778	37,567,689
Customer-based intangibles
Accumulated Amortization	$ 18,186	$ 17,277
Other Intangible Assets
Accumulated Amortization	$ 9,768	$ 7,530

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Consolidated Statements of Income - USD ($) $ in Thousands	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2016	Nov. 30, 2015
Revenues
Product revenues	$ 76,961	$ 68,717	$ 149,206	$ 133,754
Service revenues	13,756	10,893	25,156	20,717
Total Revenues	90,717	79,610	174,362	154,471
Cost of Revenues
Cost of product revenues	38,890	34,006	74,425	64,637
Cost of service revenues	8,236	7,380	15,867	13,818
Total Cost of Revenues	47,126	41,386	90,292	78,455
Gross Margin	43,591	38,224	84,070	76,016
Operating Expenses
Sales and marketing	15,687	14,203	30,484	27,774
General and administrative	8,284	6,791	16,546	13,543
Research and development	2,768	2,618	5,446	5,192
Total Operating Expenses	26,739	23,612	52,476	46,509
Operating Income	16,852	14,612	31,594	29,507
Other Income (Expense)
Interest income	296	51	419	119
Other income (expense)	(377)	(471)	(8)	(995)
Total Other Income (Expense)	(81)	(420)	411	(876)
Income Before Taxes	16,771	14,192	32,005	28,631
Provision for Income Taxes	5,600	5,050	10,900	10,200
Net Income	11,171	9,142	21,105	18,431
Net (Income) Loss Attributable to Non-Controlling Interest	(20)	(69)	(73)	(35)
Net Income Attributable to Neogen	$ 11,151	$ 9,073	$ 21,032	$ 18,396
Net Income Attributable to Neogen Per Share
Basic	$ 0.29	$ 0.24	$ 0.56	$ 0.49
Diluted	$ 0.29	$ 0.24	$ 0.55	$ 0.49

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2016	Nov. 30, 2015
Net income	$ 11,171	$ 9,142	$ 21,105	$ 18,431
Other comprehensive income (loss), net of tax: currency translation adjustments	(1,606)	(294)	(4,184)	(1,007)
Comprehensive income	9,565	8,848	16,921	17,424
Comprehensive (income) loss attributable to non-controlling interest	(20)	(69)	(73)	(35)
Comprehensive income attributable to Neogen Corporation	$ 9,545	$ 8,779	$ 16,848	$ 17,389

XML 16 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Equity - 6 months ended Nov. 30, 2016 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Non-controlling Interest
Beginning Balance at May. 31, 2016	$ 404,161	$ 6,011	$ 150,000	$ (3,946)	$ 252,133	$ (37)
Beginning Balance (in shares) at May. 31, 2016	37,567,689	37,567,689
Exercise of options, share based compensation and income tax benefit (in shares)		394,000
Exercise of options, share based compensation and income tax benefit	$ 13,263	$ 64	13,199
Issuance of shares under employee stock purchase plan (in shares)		9,000
Issuance of shares under employee stock purchase plan	428	$ 1	427
Net income	21,105				21,032	73
Other comprehensive loss	(4,184)			(4,184)
Ending Balance at Nov. 30, 2016	$ 434,773	$ 6,076	$ 163,626	$ (8,130)	$ 273,165	$ 36
Ending Balance (in shares) at Nov. 30, 2016	37,970,778	37,970,778

XML 17 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Equity (Parenthetical) $ in Thousands	6 Months Ended
	Nov. 30, 2016 USD ($)
Exercise of options, share based compensation , income tax benefit	$ 2,476

XML 18 R8.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Nov. 30, 2016	Nov. 30, 2015
Cash Flows From Operating Activities
Net income	$ 21,105	$ 18,431
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization	7,038	5,680
Share based compensation	2,734	2,545
Excess income tax benefit from the exercise of stock options	(2,476)	(2,443)
Change in operating assets and liabilities, net of business acquisitions:
Accounts receivable	1,847	2,514
Inventories	(7,963)	(8,784)
Prepaid expenses and other current assets	428	(1,858)
Accounts payable, accruals and other changes	6,836	4,776
Net Cash From Operating Activities	29,549	20,861
Cash Flows Used In Investing Activities
Purchases of property, equipment and other non-current intangible assets	(6,238)	(7,815)
Proceeds from the sale of marketable securities	64,522	80,379
Purchases of marketable securities	(67,792)	(83,916)
Business acquisitions, net of cash acquired	(437)	(13,554)
Net Cash Used In Investing Activities	(9,945)	(24,906)
Cash Flows From Financing Activities
Exercise of stock options	10,345	6,611
Excess income tax benefit from the exercise of stock options	2,476	2,443
Net Cash From Financing Activities	12,821	9,054
Effect of Exchange Rate on Cash	(1,385)	308
Net Increase In Cash and Cash Equivalents	31,040	5,317
Cash And Cash Equivalents At Beginning Of Period	55,257	66,061
Cash And Cash Equivalents At End Of Period	$ 86,297	$ 71,378

XML 19 R9.htm IDEA: XBRL DOCUMENT

Basis of Presentation

6 Months Ended

Nov. 30, 2016

Basis of Presentation

1. BASIS OF PRESENTATION

XML 20 R10.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Nov. 30, 2016

Inventories

2. INVENTORIES

Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories follow:


	November 30,		May 31,
	2016		2016
	(in thousands)
Raw Materials	$	31,881	$	29,501
Work-in-process		5,588		4,498
Finished and purchased goods		34,214		30,372

	$	71,683	$	64,371

XML 21 R11.htm IDEA: XBRL DOCUMENT

Net Income per Share

6 Months Ended

Nov. 30, 2016

Net Income per Share

3. NET INCOME PER SHARE

The calculation of net income per share attributable to Neogen Corporation follows:


	Three Months Ended				Six Months Ended
	November 30,				November 30,
	2016		2015		2016		2015
	(in thousands, except per share amounts)
Numerator for basic and diluted net income per share-
Net income attributable to Neogen	$	11,151	$	9,073	$	21,032	$	18,396
Denominator for basic net income per share-
Weighted average shares		37,816		37,390		37,715		37,301
Effect of dilutive stock options		446		478		468		509

Denominator for diluted net income per share		38,262		37,868		38,183		37,810
Net income attributable to Neogen per share:
Basic	$	0.29	$	0.24	$	0.56	$	0.49

Diluted	$	0.29	$	0.24	$	0.55	$	0.49

XML 22 R12.htm IDEA: XBRL DOCUMENT

Segment Information

6 Months Ended

Nov. 30, 2016

Segment Information

4. SEGMENT INFORMATION

Segment information follows:


					Corporate and
	Food		Animal		Eliminations
	Safety		Safety		(1)			Total
	(in thousands)
As of and for the three months ended November 30, 2016
Product revenues to external customers	$	37,279	$	39,682	$	—		$	76,961
Service revenues to external customers		3,482		10,274		—			13,756

Total revenues to external customers		40,761		49,956		—			90,717
Operating income (loss)		8,979		8,998		(1,125	)		16,852
Total assets		142,303		217,572		127,436			487,311
As of and for the three months ended November 30, 2015
Product revenues to external customers	$	34,682	$	34,035	$	—		$	68,717
Service revenues to external customers		2,572		8,321		—			10,893

Total revenues to external customers		37,254		42,356		—			79,610
Operating income (loss)		7,687		7,833		(908	)		14,612
Total assets		132,472		182,478		110,833			425,783


					Corporate and
	Food		Animal		Eliminations
	Safety		Safety		(1)			Total
	(in thousands)
For the six months ended November 30, 2016
Product revenues to external customers	$	72,921	$	76,285	$	—		$	149,206
Service revenues to external customers		6,843		18,313		—			25,156

Total revenues to external customers		79,764		94,598		—			174,362
Operating income (loss)		17,062		16,694		(2,162	)		31,594
For the six months ended November 30, 2015
Product revenues to external customers	$	66,733	$	67,021	$	—		$	133,754
Service revenues to external customers		4,981		15,736		—			20,717

Total revenues to external customers		71,714		82,757		—			154,471
Operating income (loss)		16,108		15,173		(1,774	)		29,507

(1)	Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Equity Compensation Plans

6 Months Ended

Nov. 30, 2016

Equity Compensation Plans

5. EQUITY COMPENSATION PLANS


				Weighted-
				Average
	Shares			Exercise Price
Options outstanding June 1, 2016		2,081,000		$	36.71
Granted		607,000			53.99
Exercised		(403,000	)		28.21
Forfeited		(33,000	)		40.84

Options outstanding November 30, 2016		2,252,000			42.83


	FY2017			FY2016
Risk-free interest rate		1.2	%		1.2	%
Expected dividend yield		0.0	%		0.0	%
Expected stock price volatility		35.2	%		33.3	%
Expected option life		4.0 years			4.0 years

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements

6 Months Ended

Nov. 30, 2016

New Accounting Pronouncements

6. NEW ACCOUNTING PRONOUNCEMENTS

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Business and Product Line Acquisitions

6 Months Ended

Nov. 30, 2016

Business and Product Line Acquisitions

7. BUSINESS AND PRODUCT LINE ACQUISITIONS

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Long Term Debt

6 Months Ended

Nov. 30, 2016

Long Term Debt

8. LONG TERM DEBT

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Nov. 30, 2016

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

XML 28 R18.htm IDEA: XBRL DOCUMENT

Stock Purchase

6 Months Ended

Nov. 30, 2016

Stock Purchase

10. STOCK PURCHASE

XML 29 R19.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended

Nov. 30, 2016

Inventories

The components of inventories follow:


	November 30,		May 31,
	2016		2016
	(in thousands)
Raw Materials	$	31,881	$	29,501
Work-in-process		5,588		4,498
Finished and purchased goods		34,214		30,372

	$	71,683	$	64,371

XML 30 R20.htm IDEA: XBRL DOCUMENT

Net Income per Share (Tables)

6 Months Ended

Nov. 30, 2016

Calculation of Net Income Per Share

The calculation of net income per share attributable to Neogen Corporation follows:


	Three Months Ended				Six Months Ended
	November 30,				November 30,
	2016		2015		2016		2015
	(in thousands, except per share amounts)
Numerator for basic and diluted net income per share-
Net income attributable to Neogen	$	11,151	$	9,073	$	21,032	$	18,396
Denominator for basic net income per share-
Weighted average shares		37,816		37,390		37,715		37,301
Effect of dilutive stock options		446		478		468		509

Denominator for diluted net income per share		38,262		37,868		38,183		37,810
Net income attributable to Neogen per share:
Basic	$	0.29	$	0.24	$	0.56	$	0.49

Diluted	$	0.29	$	0.24	$	0.55	$	0.49

XML 31 R21.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

6 Months Ended

Nov. 30, 2016

Segment Information

Segment information follows:


					Corporate and
	Food		Animal		Eliminations
	Safety		Safety		(1)			Total
	(in thousands)
As of and for the three months ended November 30, 2016
Product revenues to external customers	$	37,279	$	39,682	$	—		$	76,961
Service revenues to external customers		3,482		10,274		—			13,756

Total revenues to external customers		40,761		49,956		—			90,717
Operating income (loss)		8,979		8,998		(1,125	)		16,852
Total assets		142,303		217,572		127,436			487,311
As of and for the three months ended November 30, 2015
Product revenues to external customers	$	34,682	$	34,035	$	—		$	68,717
Service revenues to external customers		2,572		8,321		—			10,893

Total revenues to external customers		37,254		42,356		—			79,610
Operating income (loss)		7,687		7,833		(908	)		14,612
Total assets		132,472		182,478		110,833			425,783


					Corporate and
	Food		Animal		Eliminations
	Safety		Safety		(1)			Total
	(in thousands)
For the six months ended November 30, 2016
Product revenues to external customers	$	72,921	$	76,285	$	—		$	149,206
Service revenues to external customers		6,843		18,313		—			25,156

Total revenues to external customers		79,764		94,598		—			174,362
Operating income (loss)		17,062		16,694		(2,162	)		31,594
For the six months ended November 30, 2015
Product revenues to external customers	$	66,733	$	67,021	$	—		$	133,754
Service revenues to external customers		4,981		15,736		—			20,717

Total revenues to external customers		71,714		82,757		—			154,471
Operating income (loss)		16,108		15,173		(1,774	)		29,507

(1)	Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Equity Compensation Plans (Tables)

6 Months Ended

Nov. 30, 2016

Stock Option Activity

A summary of stock option activity during the six months ended November 30, 2016 follows:


				Weighted-
				Average
	Shares			Exercise Price
Options outstanding June 1, 2016		2,081,000		$	36.71
Granted		607,000			53.99
Exercised		(403,000	)		28.21
Forfeited		(33,000	)		40.84

Options outstanding November 30, 2016		2,252,000			42.83

Fair Value of Stock Options Granted, Estimated using Weighted-Average Assumptions

The fair value of stock options granted was estimated using the following weighted-average assumptions.


	FY2017			FY2016
Risk-free interest rate		1.2	%		1.2	%
Expected dividend yield		0.0	%		0.0	%
Expected stock price volatility		35.2	%		33.3	%
Expected option life		4.0 years			4.0 years

XML 33 R23.htm IDEA: XBRL DOCUMENT

Inventories (Detail) - USD ($) $ in Thousands	Nov. 30, 2016	May 31, 2016
Inventory [Line Items]
Raw Materials	$ 31,881	$ 29,501
Work-in-process	5,588	4,498
Finished and purchased goods	34,214	30,372
Inventories	$ 71,683	$ 64,371

XML 34 R24.htm IDEA: XBRL DOCUMENT

Calculation of Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2016	Nov. 30, 2015
Earnings Per Share [Line Items]
Numerator for basic and diluted net income per share - Net income attributable to Neogen	$ 11,151	$ 9,073	$ 21,032	$ 18,396
Denominator for basic net income per share - Weighted average shares	37,816	37,390	37,715	37,301
Effect of dilutive stock options	446	478	468	509
Denominator for diluted net income per share	38,262	37,868	38,183	37,810
Net income attributable to Neogen per share:
Basic	$ 0.29	$ 0.24	$ 0.56	$ 0.49
Diluted	$ 0.29	$ 0.24	$ 0.55	$ 0.49

XML 35 R25.htm IDEA: XBRL DOCUMENT

Segment Information - Additional Information (Detail)	6 Months Ended
Segment Information - Additional Information (Detail)	Nov. 30, 2016 Segment
Segment Reporting Information [Line Items]
Number of reportable segments	2

XML 36 R26.htm IDEA: XBRL DOCUMENT

Segment Information (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Nov. 30, 2016

Nov. 30, 2015

Nov. 30, 2016

Nov. 30, 2015

May 31, 2016

Segment Reporting Information [Line Items]

Product revenues to external customers

$ 76,961

$ 68,717

$ 149,206

$ 133,754

Service revenues to external customers

13,756

10,893

25,156

20,717

Total revenues to external customers

90,717

79,610

174,362

154,471

Operating income (loss)

16,852

14,612

31,594

29,507

Total assets

487,311

425,783

487,311

425,783

$ 451,715

Operating Segments | Food Safety

Segment Reporting Information [Line Items]

Product revenues to external customers

37,279

34,682

72,921

66,733

Service revenues to external customers

3,482

2,572

6,843

4,981

Total revenues to external customers

40,761

37,254

79,764

71,714

Operating income (loss)

8,979

7,687

17,062

16,108

Total assets

142,303

132,472

142,303

132,472

Operating Segments | Animal Safety

Segment Reporting Information [Line Items]

Product revenues to external customers

39,682

34,035

76,285

67,021

Service revenues to external customers

10,274

8,321

18,313

15,736

Total revenues to external customers

49,956

42,356

94,598

82,757

Operating income (loss)

8,998

7,833

16,694

15,173

Total assets

217,572

182,478

217,572

182,478

Corporate and Eliminations

Segment Reporting Information [Line Items]

Operating income (loss)

^[1]

(1,125)

(908)

(2,162)

(1,774)

Total assets

^[1]

$ 127,436

$ 110,833

$ 127,436

$ 110,833

[1]	Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

XML 37 R27.htm IDEA: XBRL DOCUMENT

Equity Compensation Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2016	Nov. 30, 2015	May 31, 2017	May 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense related to share based awards	$ 1,218	$ 1,248	$ 2,734	$ 2,545
Weighted-average fair value per share of stock options granted						$ 13.11
During fiscal 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value per share of stock options granted					$ 15.79
Employee Stock Purchase Plan \| 2011 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual maximum limit percentage of compensation to purchase shares			5.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period			3 years
Stock option contractual terms			5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period			5 years
Stock option contractual terms			10 years

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stock Option Activity (Detail)	6 Months Ended
Stock Option Activity (Detail)	Nov. 30, 2016 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Shares Outstanding, Beginning Balance \| shares	2,081,000
Shares, Granted \| shares	607,000
Shares, Exercised \| shares	(403,000)
Shares, Forfeited \| shares	(33,000)
Shares Outstanding, Ending Balance \| shares	2,252,000
Weighted-Average Exercise Price, Beginning Balance \| $ / shares	$ 36.71
Weighted-Average Exercise Price, Granted \| $ / shares	53.99
Weighted-Average Exercise Price, Exercised \| $ / shares	28.21
Weighted-Average Exercise Price, Forfeited \| $ / shares	40.84
Weighted-Average Exercise Price, Ending Balance \| $ / shares	$ 42.83

XML 39 R29.htm IDEA: XBRL DOCUMENT

Fair Value of Stock Options Granted, Estimated using Weighted-Average Assumptions (Detail)	12 Months Ended
	May 31, 2017	May 31, 2016
Schedule of Weighted Average Assumptions for Fair Values of Stock Options [Line Items]
Risk-free interest rate		1.20%
Expected dividend yield		0.00%
Expected stock price volatility		33.30%
Expected option life (in years)		4 years
During fiscal 2017
Schedule of Weighted Average Assumptions for Fair Values of Stock Options [Line Items]
Risk-free interest rate	1.20%
Expected dividend yield	0.00%
Expected stock price volatility	35.20%
Expected option life (in years)	4 years

XML 40 R30.htm IDEA: XBRL DOCUMENT

Business and Product Line Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands										1 Months Ended
	Dec. 27, 2016	Dec. 01, 2016	May 01, 2016	Apr. 26, 2016	Dec. 22, 2015	Aug. 26, 2015	Jun. 01, 2015	Dec. 08, 2014	Oct. 01, 2014	Jul. 31, 2016
Beijing Anapure BioScientific Co., Ltd.
Business Acquisition [Line Items]
Cash consideration for purchase of business								$ 2,040
Purchase price allocation for inventory								525
Purchase price allocation for land, property and equipment								64
Purchase price allocation for intangible assets								$ 422
Beijing Anapure BioScientific Co., Ltd. \| Minimum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life								5 years
Beijing Anapure BioScientific Co., Ltd. \| Maximum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life								15 years
Sterling Test House
Business Acquisition [Line Items]
Cash consideration for purchase of business							$ 1,118
Purchase price allocation for accounts receivable							43
Purchase price allocation for inventory							14
Purchase price allocation for land, property and equipment							141
Purchase price allocation for intangible assets							345
Contingent consideration potential payment							102
Allocation of purchase price for contingent consideration potential payment							$ 102
Cash paid for contingent consideration										$ 70
Sterling Test House \| Minimum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life							5 years
Sterling Test House \| Maximum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life							15 years
Lab M Holdings
Business Acquisition [Line Items]
Cash consideration for purchase of business						$ 12,436
Purchase price allocation for accounts receivable						975
Purchase price allocation for inventory						1,169
Purchase price allocation for land, property and equipment						3,337
Purchase price allocation for current liabilities						948
Purchase price allocation for intangible assets						3,611
Purchase price allocation for cash						285
Purchase price allocation for other current assets						309
Purchase price allocation for deferred tax liability						$ 784
Lab M Holdings \| Minimum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life						5 years
Lab M Holdings \| Maximum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life						15 years
BioLumix, Inc.
Business Acquisition [Line Items]
Cash consideration for purchase of business									$ 4,514
Purchase price allocation for accounts receivable									499
Purchase price allocation for other receivable									178
Purchase price allocation for inventory									421
Purchase price allocation for prepaid assets									48
Purchase price allocation for land, property and equipment									159
Purchase price allocation for current liabilities									155
Purchase price allocation for long-term liabilities									780
Purchase price allocation for intangible assets									$ 2,090
BioLumix, Inc. \| Minimum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life									5 years
BioLumix, Inc. \| Maximum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life									15 years
Virbac Corporation
Business Acquisition [Line Items]
Cash consideration for purchase of business					$ 3,525
Purchase price allocation for inventory					317
Purchase price allocation for land, property and equipment					60
Purchase price allocation for intangible assets					2,545
Contingent consideration potential payment					$ 300
Virbac Corporation \| Minimum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life					5 years
Virbac Corporation \| Maximum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life					15 years
Deoxi Biotecnologia Ltd
Business Acquisition [Line Items]
Cash consideration for purchase of business				$ 1,549
Purchase price allocation for accounts receivable				132
Purchase price allocation for inventory				89
Purchase price allocation for land, property and equipment				232
Purchase price allocation for current liabilities				266
Purchase price allocation for intangible assets				350
Contingent consideration potential payment				2,552
Allocation of purchase price for contingent consideration potential payment				453
Purchase price allocation for other current assets				$ 9
Deoxi Biotecnologia Ltd \| Minimum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life				5 years
Deoxi Biotecnologia Ltd \| Maximum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life				10 years
Tetradyne LLC
Business Acquisition [Line Items]
Cash consideration for purchase of business			$ 24,086
Purchase price allocation for accounts receivable			1,629
Purchase price allocation for inventory			1,964
Purchase price allocation for land, property and equipment			1,625
Purchase price allocation for current liabilities			868
Purchase price allocation for long-term liabilities			660
Purchase price allocation for intangible assets			10,590
Purchase price allocation for other current assets			$ 269
Tetradyne LLC \| Minimum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life			5 years
Tetradyne LLC \| Maximum
Business Acquisition [Line Items]
Finite lived intangible assets, useful life			15 years
Subsequent Event \| Quat-Chem Ltd.
Business Acquisition [Line Items]
Cash consideration for purchase of business		$ 20,500
Subsequent Event \| Rogama Industria e Comercio, Ltda.
Business Acquisition [Line Items]
Cash consideration for purchase of business	$ 13,000
Trademarks \| Deoxi Biotecnologia Ltd
Business Acquisition [Line Items]
Purchase price allocation for non-amortizable trademarks				$ 193

XML 41 R31.htm IDEA: XBRL DOCUMENT

Long Term Debt - Additional Information (Detail) - USD ($)		6 Months Ended
	Nov. 29, 2016	Nov. 30, 2016	May 31, 2017	May 31, 2016
Debt Instrument [Line Items]
Unsecured revolving line of credit, total amount available	$ 12,000,000	$ 15,000,000
Unsecured revolving line of credit, maturity date	Sep. 01, 2017	Sep. 30, 2019
Unsecured revolving line of credit, interest terms		LIBOR plus 100 basis points
Unsecured revolving line of credit, interest rate		1.77%
Unsecured revolving line of credit, balance outstanding		$ 0
Unsecured revolving line of credit, advances				$ 0
During fiscal 2017
Debt Instrument [Line Items]
Unsecured revolving line of credit, advances			$ 0
Libor Plus \| Unsecured Revolving Line of Credit
Debt Instrument [Line Items]
Unsecured revolving line of credit, spread		1.00%

XML 42 R32.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($)	6 Months Ended
	Nov. 30, 2016	May 31, 2016
Commitments and Contingencies Disclosure [Line Items]
Environmental remediation expense, period of remediation, years	5 years
Estimated liability costs of remediation	$ 916,000	$ 916,000
Estimated liability, measurement period, years	15 years
Estimated liability costs of remediation, current	$ 60,000	$ 60,000
Minimum
Commitments and Contingencies Disclosure [Line Items]
Environmental remediation expense	47,000
Maximum
Commitments and Contingencies Disclosure [Line Items]
Environmental remediation expense	$ 57,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stock Purchase - Additional Information (Detail) - shares	12 Months Ended
	May 31, 2017	May 31, 2016	Nov. 30, 2016	Dec. 31, 2008
Stock Repurchase Program [Line Items]
Shares authorized to purchase				1,125,000
Number of shares available to be repurchased			1,012,974
Number of shares repurchased		0
During fiscal 2017
Stock Repurchase Program [Line Items]
Number of shares repurchased	0

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller Reporting Company